Skip to main content

Q32 Bio Inc.

corporate_fare Company Profile

Q32 Bio Inc.

QTTB·NASDAQ·Life Sciences·CIK 0001661998

Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing new biologic treatments to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases caused by immune dysfunction. The company's most advanced product candidate is Bempikibart (ADX-914), a fully human anti-interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody. Bempikibart is designed to re-regulate adaptive immune function by blocking signaling from interleukin-7 (IL-7) and thymic stromal lymphopoietin (TSLP). Q32 Bio Inc. has completed two Phase 2a clinical trials for bempikibart: SIGNAL-AA Part A for AA, and SIGNAL-AD for atopic dermatitis (AD). In December 2024, the company announced topline results from both trials and its plan to advance bempikibart for AA treatment. In April 2025, dosing began for the first patients in both the Part A open-label extension and Part B of the SIGNAL-AA Phase 2a clinical trial. By October 2025, enrollment was completed in SIGNAL-AA Part B, with 33 patients enrolled, and dosing is ongoing. The company expects to report 36-week topline data from SIGNAL-AA Part B in mid-2026. In SIGNAL-AA Part A, 44 patients with severe and very severe AA were enrolled and received 200mg subcutaneous (SC) bempikibart every two weeks for 24 weeks, followed by a 12-week observation period. At the 24-week endpoint, treated patients showed more hair regrowth compared to placebo, with evidence of durable responses. Average hair regrowth continued to improve from week 24 to week 36, even after patients stopped therapy.

Q32 Bio Inc. (NASDAQ:QTTB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for QTTB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-30, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for QTTB spans 8-K, 10-Q, 424B5, S-3.

Recent high-impact activity:

  • Bempikibart Shows Durable Off-Drug Response in Phase 2a Alopecia Areata Trial
  • Q32 Bio Reports Q2 2026 Results: $106.3M Cash, $187.6M Follow-On Financing, and Bempikibart Phase 3 Runway
  • Q32 Bio Reports Q2 Results, Cash Runway Through Phase 3, and Plans for Bempikibart Registration Trial in 2027
  • Q32 Bio Prices $200M Offering at $18.25, a 63% Premium to Pre-Data Price
  • Q32 Bio Prices $200M Public Offering at $18.25/Share, Riding Positive Phase 2a Data

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$53.74M
Net Income
$29.82M
Diluted EPS
$2.42
Op. Cash Flow
-$33.54M
Free Cash Flow
-$33.54M
Operating Income
$16.9M
Cash & Equivalents
$48.3M
Debt / Equity
0.00×
Net Margin
55.5%
Shares Outstanding
12.86M sh
Source: 10-K · filed 2026-03-10 · accession 0001193125-26-099339

Short Interest & Short Volume

12.13 days to cover

FINRA reported short interest of 5,590,228 shares in QTTB as of the October 30, 2026 settlement, a 1.1% decrease from the prior period — about 12.1 days to cover at its recent average daily volume. On November 20, 2026, 65.0% of QTTB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,590,228 shares as of October 30, 2026
Change vs prior period▼ 1.1%
Days to cover12.13 at avg daily volume of 460,730
Daily short volume (FINRA facilities)65.0% of 146,192 shares on November 20, 2026
5-day average short volume51.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for QTTB, detected from its recent SEC filings · based on capital-structure filings through 2026-07-15.

1 recent capital raise2 shelf registrations

$200M Follow-On Priced at $18.25/Share · 63% Premium to Pre-Data Price

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with Q →
$8.18 -1.92% today
52-week range · as of 2026-09-30 $1.83 – $23.57
Market cap
$249.57M
Volume
476.7K (1.1× avg)
3-mo avg 436.3K
Live data · 2026-11-22 05:42 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed QTTB - Latest Insights

QTTB
Sep 30, 2026, 9:20 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.10
Real-time Price: $8.18 info
Change: -$1.92 (-19%) info
Market Cap: $249.565M info
QTTB
Aug 05, 2026, 7:09 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.30
Real-time Price: $8.18 info
Change: -$8.12 (-50%) info
Market Cap: $249.565M info
QTTB
Aug 05, 2026, 6:59 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $16.30
Real-time Price: $8.18 info
Change: -$8.12 (-50%) info
Market Cap: $249.565M info
QTTB
Jul 15, 2026, 5:23 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $16.06
Real-time Price: $8.18 info
Change: -$7.88 (-49%) info
Market Cap: $249.565M info
QTTB
Jul 15, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $16.06
Real-time Price: $8.18 info
Change: -$7.88 (-49%) info
Market Cap: $249.565M info
QTTB
Jul 15, 2026, 5:11 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $16.06
Real-time Price: $8.18 info
Change: -$7.88 (-49%) info
Market Cap: $249.565M info
QTTB
Jul 14, 2026, 10:58 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $18.46
Real-time Price: $8.18 info
Change: -$10.28 (-56%) info
Market Cap: $249.565M info
QTTB
Jul 13, 2026, 4:01 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $22.17
Real-time Price: $8.18 info
Change: -$13.99 (-63%) info
Market Cap: $249.565M info
QTTB
Jul 13, 2026, 8:39 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $19.28
Real-time Price: $8.18 info
Change: -$11.10 (-58%) info
Market Cap: $249.565M info
QTTB
Jul 13, 2026, 7:14 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $19.31
Real-time Price: $8.18 info
Change: -$11.13 (-58%) info
Market Cap: $249.565M info
QTTB
Jul 13, 2026, 7:09 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $18.19
Real-time Price: $8.18 info
Change: -$10.01 (-55%) info
Market Cap: $249.565M info
QTTB
Jul 10, 2026, 4:05 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $11.16
Real-time Price: $8.18 info
Change: -$2.98 (-27%) info
Market Cap: $249.565M info
QTTB
Jun 25, 2026, 4:11 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $11.95
Real-time Price: $8.18 info
Change: -$3.77 (-32%) info
Market Cap: $249.565M info
QTTB
Jun 01, 2026, 9:15 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $11.67
Real-time Price: $8.18 info
Change: -$3.49 (-30%) info
Market Cap: $249.565M info
QTTB
Jun 01, 2026, 9:13 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $11.67
Real-time Price: $8.18 info
Change: -$3.49 (-30%) info
Market Cap: $249.565M info
QTTB
Jun 01, 2026, 9:10 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $11.67
Real-time Price: $8.18 info
Change: -$3.49 (-30%) info
Market Cap: $249.565M info
QTTB
May 28, 2026, 4:28 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $10.31
Real-time Price: $8.18 info
Change: -$2.13 (-21%) info
Market Cap: $249.565M info
QTTB
May 27, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $13.32
Real-time Price: $8.18 info
Change: -$5.14 (-39%) info
Market Cap: $249.565M info
QTTB
May 27, 2026, 8:00 AM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $7.35
Real-time Price: $8.18 info
Change: +$0.830 (+11%) info
Market Cap: $249.565M info
QTTB
May 05, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.11
Real-time Price: $8.18 info
Change: +$3.07 (+60%) info
Market Cap: $249.565M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets